XORTX Initiates IND Preparation for XORLO™ in Gout Program
1. XORTX initiates IND preparation for gout treatment XRx-026. 2. The FDA provided guidance for NDA submission of XORLO™. 3. Allucent engaged for regulatory expertise on IND and NDA. 4. 73,871 shares issued under ATM offering for proceeds of USD 113,547. 5. Gout prevalence in the U.S. expected to double in 25 years.